Oral chemotherapeutic agents comprise 25% to 35% of oncology drugs in development. They are an increasingly vital component of anticancer treatment and are anticipated to play an even larger role in the longer term. The transition from intravenous (IV) to oral agents presents challenges for oncology care managers, including varied patient perceptions and preferences for mode of delivery, the impact on hospital and delivery system revenues, out-of-pocket (OOP) costs as potential access barriers, Medicare Part D challenges, regulatory policy issues, medication adherence challenges, and the development of side effects. These challenges assume greater urgency considering a recent PRECISIONvalue survey that identified oncology as the top disease area driving patient referrals for care management.

This white paper is based on a webinar convened by PRECISIONvalue, featuring in-house experts in oncology and patient access. Moderated by Dominic Galante, MD, Chief Medical Officer for the PRECISIONvalue Access Experience Team, the webinar included the following panelists:

• Christy Banach, Senior Director, Access Experience Team
• Maureen Hennessey, Senior Vice President, Director, Value Transformation
• Janet Serluco, Vice President, Oncology Lead, Access Experience Team
• Jennifer Williams, Vice President, Access Experience Team

Read Now!